Výsledky vyhledávání - "Monika, Mentze"

Akademický článek

Prediction of clinical response to drugs in ovarian cancer using the chemotherapy resistance test (CTR-test)

Autor: Frank Christian Kischkel, Carina Meyer, Julia Eich, Mani Nassir, Monika Mentze, Ioana Braicu, Annette Kopp-Schneider, Jalid Sehouli

Publikováno v: Journal of Ovarian Research, Vol 10, Iss 1, Pp 1-9 (2017)

Abstract Background In order to validate if the test result of the Chemotherapy Resistance Test (CTR-Test) is able to predict the resistances or sensitivities of tumors in ovarian cancer patients to drugs, the CTR-Test result and the corresponding cl

Externí odkaz: https://doaj.org/article/2e085aabc5a94feb91cfb039cc992b6e

Zobrazit plný text záznamu

The Role of PAR1 Autoantibodies in Patients with Primary Epithelial Ovarian Cancer

Autor: Katrin Kreienbring, Jalid Sehouli, Dominik N. Müller, Elena Ioana Braicu, Ralf Dechend, Rolf Richter, Annika Franz, Harald Heidecke, Monika Mentze, Duska Dragun

Publikováno v: Anticancer research. 38(6)

AIM This study aimed to analyze the predictive, prognostic and diagnostic value of autoantibodies to coagulation factor II thrombin receptor (F2R; protease-activated receptor 1, PAR1) (PAR1-AB) in patients with primary epithelial ovarian cancer (EOC)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fcc210910eb90649eb874113d023e852
https://pubmed.ncbi.nlm.nih.gov/29848718

Zobrazit plný text záznamu

HIF1α is an independent prognostic factor for overall survival in advanced primary epithelial ovarian cancer – a study of the OVCAD Consortium

Autor: Dan Cacsire Castillo-Tong, Jalid Sehouli, Rolf Richter, Ignace Vergote, Robert Zeillinger, Sven Mahner, Elena Ioana Braicu, Nicole Concin, Monika Mentze, Hrvoje Luketina, Sandrina Lambrechts

Publikováno v: OncoTargets and therapy

Elena Ioana Braicu,1 Hrvoje Luketina,1 Rolf Richter,1 Dan Cacsire Castillo-Tong,2 Sandrina Lambrechts,4 Sven Mahner,5 Nicole Concin,6 Monika Mentze,1 Robert Zeillinger,2,3 Ignace Vergote,4 Jalid Sehouli1 1Department of Gynecology, European Competence

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8547401f9631cd96f799f280be8cb21b
https://www.dovepress.com/hif1alpha-is-an-independent-prognostic-factor-for-overall-survival-in--peer-reviewed-article-OTT

Zobrazit plný text záznamu

Role of serum VEGFA, TIMP2, MMP2 and MMP9 in monitoring response to adjuvant radiochemotherapy in patients with primary cervical cancer--results of a companion protocol of the randomized NOGGO-AGO phase III clinical trial

Autor: Elena Ioana, Braicu, Khayal, Gasimli, Rolf, Richter, Mani, Nassir, Sherko, Kümmel, Jens-Uwe, Blohmer, Isil, Yalcinkaya, Radoslav, Chekerov, Iulia, Ignat, Andra, Ionescu, Monika, Mentze, Christina, Fotopoulou, Carmen, Pop, Werner, Lichtenegger, Jalid, Sehouli

Publikováno v: Anticancer research. 34(1)

The aim of the current study was to analyze the type of variations in expression profiles of matrix metalloproteinase 2 (MMP2), matrix metalloproteinase 9 (MMP9), tissue inhibitor of metalloproteinase 2 (TIMP2), and vascular endothelial growth factor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::50c24a15a1e79e95db2d5c66338c6f73
https://pubmed.ncbi.nlm.nih.gov/24403492

Zobrazit plný text záznamu

Role of serum concentration of VEGFR1 and TIMP2 on clinical outcome in primary cervical cancer: results of a companion protocol of the randomized, NOGGO-AGO phase III adjuvant trial of simultaneous cisplatin-based radiochemotherapy vs. carboplatin and paclitaxel containing sequential radiotherapy

Autor: Sherko Kümmel, Christina Fotopoulou, Monika Mentze, Rolf Richter, Isil Yalcinkaya, Radoslav Chekerov, Florin Stamatian, Werner Lichtenegger, Jens Uwe Blohmer, Jalid Sehouli, Elena-Ioana Braicu

Publikováno v: Cytokine. 61(3)

Objective Aim of the present study was to analyze the expression-profile of IGF1, IGFBP3, sICAM1, sVCAM1, MMP2, MMP9, TIMP2, VEGFA, VEGFD, VEGFC and VEGFR1 in patients with high-risk FIGO-stage Ib-IIb cervical cancer. Methods Serum from 68 cervical c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fffedb4d55120fb9bca7d9e8ad1ff92e
https://pubmed.ncbi.nlm.nih.gov/23415672

Zobrazit plný text záznamu

Prognostic value of serum and ascites levels of estradiol, FSH, LH and prolactin in ovarian cancer

Autor: Frank Chih-Kang, Chen, Guelten, Oskay-Ozcelik, Kai J, Bühling, Uta, Köpstein, Monika, Mentze, Werner, Lichtenegger, Jalid, Sehouli

Publikováno v: Anticancer research. 29(5)

The aim of this study was to investigate the influence of sex hormone levels on tumor biology and patients' outcome in ovarian cancer.One hundred and six patients with ovarian cancer were enrolled into this prospective study. Serum and ascites sample

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::66c9b6ac7d660909771d208b29344baf
https://pubmed.ncbi.nlm.nih.gov/19443368

Zobrazit plný text záznamu

Does overexpression of VEGFR and TIMP2 predict survival in primary cervical cancer (CC) patients? Results of a companion protocol of the randomized, phase III adjuvant trial of simultaneous cisplatin radiochemotherapy versus sequential carboplatin and paclitaxel followed by radiotherapy

Autor: J-U Blohmer, Klaus Pietzner, Radoslav Chekerov, Christina Fotopoulou, Jalid Sehouli, G. Oskay-Özcelik, Monika Mentze, C. Pop, S. Kuemmel, Werner Lichtenegger, Oumar Camara, Toc Noggo, Rolf Richter, Elena-Ioana Braicu

Publikováno v: Journal of Clinical Oncology. 29:e15507-e15507

e15507 Background: Aim of the study was to analyse the expression-profile of IGF1, IGFBP3, sICAM1, sVCAM1, MMP2, MMP9, TIMP2, VEGF, VEGFD, VEGFC and VEGFR in patients with FIGO-stage high-risk Ib-I...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::352787883cbbacd3096cc97ed4724811
https://doi.org/10.1200/jco.2011.29.15_suppl.e15507

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání